Pluri Inc. 8-K Filing Summary
Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on June 30, 2025, and July 2, 2025, regarding Pluri Inc. (Nasdaq: PLUR). The filing details the outcomes of the Company's 2025 Annual Meeting of Shareholders held on June 30, 2025, and subsequent regulatory notifications to Nasdaq.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance, shareholder voting results, and listing compliance matters.
Material Changes and Governance Events
- Director Departure: Mr. Doron Birger was not re-elected to the Board of Directors. He ceased serving as a director, Chairman of the Audit Committee, and sole member of the Investment Committee effective June 30, 2025.
- Nasdaq Non-Compliance: Due to Mr. Birger's departure, the Company is no longer in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires the Audit Committee to have at least three independent directors.
- Cure Period: Nasdaq granted a cure period to regain compliance, expiring on the earlier of the next annual meeting or June 30, 2026. The Company intends to appoint an additional independent director before this deadline.
- Shareholder Voting Results:
- Proposal 1 (Directors): Zami Aberman, Rami Levi, Maital Shemesh-Rasmussen, Yaky Yanay, and Alexandre Weinstein were elected. Doron Birger received 1,270,717 votes "For" and 2,720,350 votes "Against."
- Proposal 2 (Auditor): Ratification of Kesselman & Kesselman as independent auditors passed with 5,164,886 "For" votes.
- Proposal 3 (Equity Plan): Approval of the 2016 Equity Compensation Plan passed with 3,914,964 "For" votes.
- Proposal 4 (Say-on-Pay): Advisory vote on executive compensation passed with 3,919,160 "For" votes.
- Proposal 5 (Frequency of Say-on-Pay): Shareholders voted for a frequency of every two years (2,403,566 votes), determining the next advisory vote will occur in 2027.
- Proposal 6 (Warrant Exercise): Approval for the exercise of warrants to purchase up to 1,086,768 common shares related to a private placement with an entity owned by Mr. Alexandre Weinstein passed with 3,530,251 "For" votes.
Outlook, Risks, and Contingencies
The primary risk identified is the potential delisting or failure to satisfy continued listing standards if the Company fails to appoint a new independent director to the Audit Committee within the Nasdaq cure period. The Company has stated its intention to appoint an additional independent director prior to the expiration of the cure period to maintain compliance.
Key Facts for Investor Verification
- Verify the timeline for the appointment of a new independent director to the Audit Committee to ensure compliance with Nasdaq rules by June 30, 2026.
- Confirm the impact of Mr. Birger's departure on the Company's Investment Committee, as he was the sole member.
- Review the details of the private placement warrant exercise approved in Proposal 6 to understand the dilution impact of the 1,086,768 shares.
- Note that the next advisory vote on executive compensation is scheduled for the 2027 annual meeting.